Article Text

Download PDFPDF

206 Novel intermediate-avidity glypican-3 specific CARTs resist exhaustion and mediate durable antitumor effects against human hepatocellular carcinoma
  1. Leidy Caraballo-Galva1,
  2. Xiaotao Jiang1,
  3. Mohamed Hussein1,
  4. Huajun Zhang2,
  5. Rui Mao1,
  6. Pierce Brody1,
  7. Yibing Peng1,
  8. AIwu He3,
  9. Mercy Kehinde-Ige1,
  10. Ramses Sadek1,
  11. Xiangguo Qiu2,
  12. Huidong Shi1 and
  13. Yukai He1
  1. 1Augusta University, Augusta, GA, USA
  2. 2University of Manitoba, Winnipeg, Canada
  3. 3Georgetown University, Washington DC, USA


Background Despite intensive effort, current chimeric antigen receptor modified T cells (CARTs) do not work well for solid tumors. In blood cancers, CARTs easily access to target cells and can “take a break” after each killing of individual tumor cells. In contrast, solid tumor mass limits CART infiltration and create a persistent and multi-dimensional engagement between CART and tumor cells. After CARTs manage infiltrate into tumor mass, they are surrounded by tumor cells, and their movement is further restrained by tumor stroma matrix, which force them under constant stimulation and drive them into exhaustion and death. Conventionally, most CARTs are built from high-affinity monoclonal antibodies (mAb). While such high-avidity CARTs may detect and kill tumor cells of low antigen, they are more prone to exhaustion and death in solid tumors. The aims of this study is to develop proper intermediate-affinity mAbs and intermediate-avidity CARTs for hepatocellular carcinoma (HCC), the 3rd leading cause of cancer death and to test the hypothesis that intermediate-avidity CARTs can resist exhaustion and apoptosis and maintain functions in solid tumors, generating more durable antitumor effects.

Methods We developed 3 new human glypican-3 (hGPC3)-specific mAbs from immunized mice. The mAbs only stained HCC tumors, but not the adjacent normal liver tissues. One of them, 8F8, bound an epitope close to that of GC33, the frequently used high-affinity mAb, but with ~17 fold lower affinity. We then built and compared the intermediate-avidity 8F8 CARTs to high-avidity GC33 CARTs for their in vitro function and antitumor effects (1).

Results In vitro, 8F8 CARTs killed both hGPC3high and hGPC3low HCC cells to the same extent as GC33 CARTs, but produced lower cytokines. However, the expansion of 8F8 CARTs was 3-5 folds more than GC33 CARTs after engaging with target cells. 8F8 CARTs were less exhausted and less apoptotic than high-avidity GC33 CARTs. The expansion advantage of 8F8 CARts was maintained under hypoxia culture condition. Importantly, the 8F8 CARTs also expanded and persisted to a greater extent than GC33 CARTs in vivo, resulting in durable responses against HCC xenografts. Compared to GC33 CARTs, there were 5 folds more 8F8-BBz CARTs in the tumor mass for a longer period of time (figure 1). Remarkably, the tumor infiltrating 8F8 CARTs were much less exhausted and apoptotic, and more functional than GC33 CARTs.

Conclusions The novel intermediate-avidity 8F8-BBz CART resists exhaustion and apoptosis inside solid tumors, demonstrating a greater and durable therapeutic potential than high-avidity CARTs.


  1. Caraballo Galva, L.D., et al. (2022) Novel low-avidity glypican-3 specific CARTs resist exhaustion and mediate durable antitumor effects against HCC. Hepatology 76(2), 330-44

Abstract 206 Figure 1

More functional 8F8-BBz CARTs are in tumors.More functional 8F8-BBz CARTs are in tumors.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.